Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer.
作者信息
Fala Loretta
出版信息
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):176-9.
Abstract
摘要
相似文献
1
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer.乐伐替尼（仑伐替尼），一种多受体酪氨酸激酶抑制剂，已获美国食品药品监督管理局批准用于治疗分化型甲状腺癌患者。
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):176-9.
2
[Lenvatinib in radioiodine refractory thyroid carcinomas].[乐伐替尼用于放射性碘难治性甲状腺癌]
Bull Cancer. 2016 Nov;103(11):905-910. doi: 10.1016/j.bulcan.2016.10.002. Epub 2016 Nov 3.
3
FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.FDA 批准概要：仑伐替尼用于进展性、放射性碘难治性分化型甲状腺癌。
Clin Cancer Res. 2015 Dec 1;21(23):5205-8. doi: 10.1158/1078-0432.CCR-15-1377. Epub 2015 Aug 31.
4
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.仑伐替尼、索拉非尼和安慰剂治疗碘难治性分化型甲状腺癌的成本效果分析。
Thyroid. 2017 Aug;27(8):1043-1052. doi: 10.1089/thy.2016.0572. Epub 2017 Jun 7.
5
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.甲状腺癌中新获批的酪氨酸激酶抑制剂的毒性与临床获益之间的关系：一项文献荟萃分析
J Cancer Res Ther. 2015 Oct;11 Suppl 2:C185-90. doi: 10.4103/0973-1482.168182.
6
Lenvatinib: A Review in Refractory Thyroid Cancer.乐伐替尼：难治性甲状腺癌的综述
Target Oncol. 2016 Feb;11(1):115-22. doi: 10.1007/s11523-015-0416-3.
7
Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.仑伐替尼——一种用于放射性碘难治性分化型甲状腺癌的多激酶抑制剂。
J Oncol Pharm Pract. 2018 Jan;24(1):28-32. doi: 10.1177/1078155216680119. Epub 2016 Nov 18.
8
Lenvatinib: Role in thyroid cancer and other solid tumors.乐伐替尼：在甲状腺癌和其他实体肿瘤中的作用。
Cancer Treat Rev. 2016 Jan;42:47-55. doi: 10.1016/j.ctrv.2015.11.003. Epub 2015 Dec 2.
9
Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.胃肠穿孔与仑伐替尼相关，仑伐替尼是一种抗血管生成抑制剂，针对多种受体酪氨酸激酶，用于治疗转移性甲状腺癌患者。
Invest New Drugs. 2018 Apr;36(2):350-353. doi: 10.1007/s10637-017-0522-4. Epub 2017 Oct 11.
10
Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?乐伐替尼：治疗晚期碘难治性分化型甲状腺癌的新选择？
Future Oncol. 2015;11(12):1719-27. doi: 10.2217/fon.15.68.
引用本文的文献
1
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.仑伐替尼联合帕博利珠单抗是治疗间变性和低分化甲状腺癌的有效治疗选择。
Thyroid. 2021 Jul;31(7):1076-1085. doi: 10.1089/thy.2020.0322. Epub 2021 Apr 15.
2
Fournier's gangrene during lenvatinib treatment: A case report.乐伐替尼治疗期间发生的福尼尔坏疽：一例报告。
Mol Clin Oncol. 2020 Jun;12(6):588-591. doi: 10.3892/mco.2020.2031. Epub 2020 Apr 10.
3
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.放射性碘治疗后的分化型甲状腺癌采用仑伐替尼和索拉非尼治疗：系统评价和经济评估。
Health Technol Assess. 2020 Jan;24(2):1-180. doi: 10.3310/hta24020.
4
The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis.肿瘤血管靶向策略：肿瘤转移的双刃剑。
Cells. 2019 Dec 10;8(12):1602. doi: 10.3390/cells8121602.
5
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials.乐伐替尼治疗肝细胞癌的概况：所有III期试验中乙型肝炎和丙型肝炎的设计、研发、治疗中的潜在地位及网状meta分析
Onco Targets Ther. 2019 Apr 24;12:2981-2988. doi: 10.2147/OTT.S192572. eCollection 2019.
6
Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety.一些含喹喔啉二酮部分的新型二芳基脲衍生物的合成与表征
Res Pharm Sci. 2018 Feb;13(1):82-92. doi: 10.4103/1735-5362.220971.
7
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.癌症治疗：抗血管生成与靶向治疗联合策略
Front Cell Dev Biol. 2017 Dec 7;5:101. doi: 10.3389/fcell.2017.00101. eCollection 2017.
本文引用的文献
1
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.乐伐替尼对比安慰剂用于碘难治性甲状腺癌。
N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.
2
Annual financial impact of well-differentiated thyroid cancer care in the United States.美国分化型甲状腺癌治疗的年度经济影响。
Cancer. 2014 May 1;120(9):1345-52. doi: 10.1002/cncr.28562. Epub 2014 Jan 30.
3
The clinical and economic burden of a sustained increase in thyroid cancer incidence.甲状腺癌发病率持续增加的临床和经济负担。
Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1252-9. doi: 10.1158/1055-9965.EPI-13-0242. Epub 2013 May 15.
4
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
5
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.444例乳头状和滤泡状甲状腺癌远处转移患者的长期预后：放射性碘治疗的益处和局限性
J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9. doi: 10.1210/jc.2005-2838. Epub 2006 May 9.
Zotero 插件